Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study maps lymphoma care gaps in MEA region

NCT ID NCT07065344

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study will look at 500 people with diffuse large B-cell lymphoma (DLBCL) in the Middle East and Africa. Researchers want to understand patient characteristics, current treatment patterns, and how easily patients can access newer therapies like CAR-T cell therapy. The study does not test any new drug or treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This study could help doctors better understand how DLBCL is treated in the Middle East and Africa, and identify barriers to newer therapies.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or directly improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study aims to recruit approximately 500 patients, divided as follows: * Cohort 1: 333 patients treatment naïve, treatment-eligible DLBCL patients. * Cohort 2: 167 patients relapsed and/or refractory DLBCL patients who have failed at least one prior therapy. Patients will be selected based on strict inclusion and exclusion criteria to ensure the validity and reliability of the study results. The study will be conducted across eight countries in the Middle East and Africa (MEA) region, including Egypt, South Africa, Turkey, Iraq, Morocco, and the Gulf Cooperative Council (GCC), including the Kingdom of Saudi Arabia (KSA), the United Arab Emirates (UAE), and Kuwait. Approximately 15-20 sites within these countries will participate in the study.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female patients aged 18 years or older at diagnosis. 2. Patients who have confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) according to the investigator's decision and/or histopathological diagnosis. 3. For Cohort 1: DLBCL patients who are eligible to start treatment\* according to the investigator's decision. 4. For Cohort 2: patients who are diagnosed with DLBCL and have failed at least one prior line of therapy. 5. Patients willing to sign the written informed consent form (ICF) indicating that they understand the purpose of the study and procedures required for participation. Exclusion Criteria: 1. Patients who are not eligible for treatment for any reason, according to the investigator's judgment and decision 2. Patients with concurrent active malignancies other than DLBCL. 3. Patients who are actively participating in any other clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffused large B cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma hematologic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffused large B cell lymphoma Hematology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites in 10 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Al Mansurah, Egypt

  • Research Site

    NOT_YET_RECRUITING

    Alexandria, Egypt

  • Research Site

    NOT_YET_RECRUITING

    Cairo, Egypt

  • Research Site

    NOT_YET_RECRUITING

    Sohag, Egypt

  • Research Site

    NOT_YET_RECRUITING

    Tanta, Egypt

  • Research Site

    NOT_YET_RECRUITING

    Baghdad, Iraq

  • Research Site

    RECRUITING

    Amman, Jordan

  • Research Site

    NOT_YET_RECRUITING

    Kuwait City, Kuwait

  • Research Site

    NOT_YET_RECRUITING

    Casablanca, Morocco

  • Research Site

    NOT_YET_RECRUITING

    Rabat, Morocco

  • Research Site

    RECRUITING

    Muscat, Oman

  • Research Site

    RECRUITING

    Doha, Qatar

  • Research Site

    RECRUITING

    Dammam, Saudi Arabia

  • Research Site

    RECRUITING

    Jeddah, Saudi Arabia

  • Research Site

    RECRUITING

    Riyadh, Saudi Arabia

  • Research Site

    NOT_YET_RECRUITING

    Riyadh, Saudi Arabia

  • Research Site

    RECRUITING

    Ankara, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Antalya, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Istanbul, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Izmir, Turkey (Türkiye)

  • Research Site

    RECRUITING

    Abu Dhabi, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.